ClinicalTrials.gg
RecruitingNCT07554183PORTAL-4DUpdated Oct 13, 2026

4D-Flow MRI Assessment of Portal Hypertension and TIPS Outcomes in Cirrhosis

An interventional study of 4D-Flow Liver and heart MRI with Gadolinium injection and Samples Without DNA in Cirrhosis and Portal Hypertension, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Primary conditionHypertension, PortalRegistry: FibrosisReclassifiedWhy we changed it
Registry
Fibrosis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypertension, Portal
Why
  1. Fibrosis is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Hypertension, Portal.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Assistance Publique - Hôpitaux de Paris · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Hypertension, Portal with a site in France — 6 open to participants now, 8 under way, 1 of them phase 3. Hypertension, Portal · France.

Planned enrollment
17th of 20
60 · median 121
Started
2026
with 1 other
No phase
13 of 26
3 open now
Registered
25th of 26
by date
Lead sponsor
6 of 26
Assistance Publique - Hôpitaux de Paris

Among the 26 studies in Hypertension, Portal with a site in France, this one is the 17th largest by planned enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2026, is one of 13 with no phase, and was the 25th registered.

Hypertension, Portal

376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.

Browse Hypertension, Portal studies →

Open to participants now

6 of the 26 studies in Hypertension, Portal with a site in France are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 68 Hypertension, Portal studies recruiting now, 33 (49%) set no upper age limit and 12 (18%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Hypertension, Portal with a site in France, or all of them as a file.
02

Study summary

PORTAL-4D is a prospective, interventional, non-randomized, parallel-group diagnostic study conducted at Pitié-Salpêtrière Hospital (Paris, France).

Portal hypertension is the main driver of hepatic decompensation and is associated with ascites, variceal bleeding, hepatic encephalopathy, and reduced survival. The current gold standard for assessing portal hypertension is the invasive hepatic venous pressure gradient (HVPG) measurement performed via the transjugular route. However, HVPG is invasive, operator-dependent, and limited to specialized centers. A reliable non-invasive alternative is therefore highly needed.

60 adults patients with cirrhosis will be enrolled and divided into two parallel groups: MASLD group (n=24): Patients with compensated cirrhosis related to metabolic dysfunction-associated steatotic liver disease (MASLD).

TIPS group (n=36): Patients with decompensated cirrhosis referred for transjugular intrahepatic portosystemic shunt (TIPS) placement.

The primary objective is to assess the correlation between invasive HVPG values and 4D-flow MRI parameters. Secondary objectives include evaluating the prognostic value of 4D-flow MRI in predicting portal hypertension-related complications and post-TIPS outcomes within 6 months.

The study is expected to validate 4D-flow MRI as an non-invasive diagnostic and prognostic tool for portal hypertension, potentially improving patient selection for TIPS and reducing reliance on invasive procedures.

Read the detailed description

Portal hypertension is the main determinant of hepatic decompensation in cirrhotic patients and is associated with major complications such as variceal gastrointestinal bleeding, refractory ascites, hepatic encephalopathy, and liver-related mortality. The reference standard for assessing clinically significant portal hypertension is the invasive hepatic venous pressure gradient (HVPG), measured via the transjugular route. HVPG reflects the hemodynamic consequences of increased intrahepatic resistance and portal inflow and has strong prognostic value. An HVPG ≥10 mmHg defines clinically significant portal hypertension and is associated with a higher risk of decompensation and mortality. In patients treated with TIPS, achieving a post-procedural gradient \<12 mmHg or a reduction of at least 50% from baseline is associated with a decreased risk of rebleeding and other complications.

Despite its clinical relevance, HVPG measurement is invasive, requires specialized expertise, and is not widely available. Moreover, it may not capture the full complexity of portal and systemic hemodynamics. Consequently, there is a critical unmet need for non-invasive, reproducible, and operator-independent techniques capable of assessing portal hypertension and guiding clinical decision-making.

4D-flow MRI is an advanced imaging technique that enables time-resolved, three-dimensional quantification of blood flow in multiple vascular territories within a single acquisition. In the hepatic and splanchnic circulation, it allows comprehensive measurement of portal vein, splenic vein, superior mesenteric vein, hepatic veins, and inferior vena cava flow, including velocities, flow volumes, and shunt fractions. Preliminary studies have demonstrated the feasibility and reproducibility of 4D-flow MRI in evaluating portal hemodynamics, but robust validation against invasive HVPG and prospective prognostic evaluation remain limited.

The study will enroll 60 adult patients with confirmed cirrhosis, divided into two parallel groups:

MASLD Group (n=24) participants will undergo transjugular HVPG measurement (performed specifically for research purposes), hepatic 4D-flow MRI with gadolinium contrast, and standardized blood sampling. They will be followed for 6 months to evaluate the occurrence of portal hypertension-related events, including ascites requiring intervention, variceal bleeding, hepatic encephalopathy, and liver-related death.

TIPS Group (n=36) participants will undergo 4D-flow MRI within 3 days prior to TIPS and again 3 days after the procedure. Invasive pressure measurements (including right atrial pressure, free and wedged hepatic venous pressures, and portal pressure when applicable) will be performed before and immediately after TIPS placement, as well as at day 3. Clinical and biological follow-up will continue for 6 months to assess post-TIPS outcomes and complications, including hepatic encephalopathy, cardiac dysfunction, persistent portal hypertension, and liver-related events.

The primary objective is to evaluate the correlation between invasive HVPG measurements and quantitative hemodynamic parameters derived from 4D-flow MRI. Agreement between techniques will be assessed using correlation coefficients and Bland-Altman analysis.

In addition, multi-omics analyses (proteomic, metabolomic, transcriptomic, and metagenomic profiling) will be performed on systemic, suprahepatic, and portal blood samples to identify biological signatures associated with hepatic encephalopathy and clinical decompensation.

By validating 4D-flow MRI as a non-invasive surrogate for HVPG and as a prognostic tool for portal hypertension-related complications, PORTAL-4D aims to improve risk stratification, optimize patient selection for TIPS, and potentially reduce reliance on invasive procedures. The integration of advanced imaging and multi-omics profiling may also provide new insights into the pathophysiology of hepatic encephalopathy and shunt-related complications, contributing to a more personalized and physiology-driven management of cirrhotic patients.

03

Conditions studied

  • Cirrhosis
  • Portal Hypertension

Browse trials for

Keywords

  • 4D-Flow MRI
  • Hepatic Venous Pressure Gradient
  • Portal Hemodynamics
  • Noninvasive Liver Imaging
  • Hepatic Encephalopathy
  • Portal hypertension complications
  • TIPS
  • MASLD
04

In context

Hypertension, Portal Reclassified

376 studies on the registry are indexed under Hypertension, Portal; 114 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 232 interventional studies indexed under Hypertension, Portal.

Browse Hypertension, Portal studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.

Compared within Hypertension, Portal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fibrosis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Applicable to both groups :

  1. Age ≥ 18 years
  2. Eligible to undergo MRI examination
  3. Prior clinical evaluation completed
  4. Covered by a national health insurance scheme or beneficiary thereof (excluding State Medical Aid AME)
  5. Patient informed and written obtained

    Specific to the MASLD group :

  6. Indication for TIPS validated during a multidisciplinary team meeting and documented in the patient's medical record, including one of the following:

    • ascites
    • Hepatic hydrothorax
    • Failure of secondary prophylaxis of variceal gastrointestinal bleeding
    • Preemptive TIPS
    • Preoperative TIPS

    Specific to the MASLD group :

  7. Past or current exposure to metabolic risk factors (overweight, obesity, type 2 diabetes mellitus, arterial hypertension, dyslipidemia)
  8. Liver stiffness > 15 kPa measured by transient elastography
  9. Liver documenting steatosis with stage 3 fibrosis or cirrhosis
  10. Alcohol consumption \< 20 g/day for women and \< 30 g/day for men, assessed using validated routine clinical questionnaires

Exclusion criteria

Exclusion Criteria:

Applicable to both groups :

  1. Any to MRI (cardiac pacemaker, implantable cardioverter-defibrillator, cochlear implants, intraocular metallic foreign bodies, intracranial vascular clips).
  2. Prior liver transplantation.
  3. Pregnancy, breastfeeding, or women of not using effective .
  4. Individual under legal guardianship or trusteeship, or unable to provide .
  5. Participation in another interventional clinical study or currently within the exclusion period following a previous ongoing study.

    Specific to the TIPS group

  6. Patients undergoing salvage TIPS placement in the setting of hemorrhagic shock. Specific to the MASLD group
  7. Other etiologies of chronic liver disease, including viral hepatitis, liver disease, or hemochromatosis
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    TIPS group

    TIPS group : Adults with decompensated cirrhosis referred for transjugular intrahepatic portosystemic shunt (TIPS). Participants undergo 4D-flow liver MRI before and after TIPS placement, invasive pressure measurements, blood sampling, and 6-month follow-up to assess post-TIPS outcomes.

    Other: 4D-Flow Liver and heart MRI with Gadolinium injection · Biological: Samples Without DNA

  • Experimental
    MASLD group

    MASLD group : Adults with compensated cirrhosis related to metabolic dysfunction-associated steatotic liver disease (MASLD). Participants undergo invasive HVPG measurement and 4D-flow liver MRI, with 6-month follow-up to assess portal hypertension-related complications and prognostic value of imaging parameters.

    Other: 4D-Flow Liver and heart MRI with Gadolinium injection · Biological: Samples Without DNA

Interventions

  • Other4D-Flow Liver and heart MRI with Gadolinium injection

    Non-invasive hepatic 4D-flow magnetic resonance imaging performed with gadolinium contrast to quantify portal and systemic venous blood flow, velocities, and shunt fraction. Measurements are compared with invasive hepatic venous pressure gradient (HVPG) values and clinical outcomes to assess diagnostic accuracy and prognostic value for portal hypertension-related complications.

  • BiologicalSamples Without DNA

    Portal, hepatic and systemic veins blood collection

07

What researchers measure

Primary outcomes

  1. Correlation between invasive hepatic venous pressure gradient (HVPG) and quantitative hepatic 4D-flow MRI hemodynamic parameters

    The primary outcome is the association between the invasive hepatic venous pressure gradient (HVPG; wedged hepatic venous pressure minus free hepatic venous pressure) measured during transjugular catheterization and quantitative hepatic 4D-flow MRI-derived parameters, including flow rate and peak velocity in the portal venous system (main portal vein and right/left branches), splenic vein, superior mesenteric vein, hepatic veins, and inferior vena cava. When available, direct portal pressure will be recorded as supportive invasive data

    Time frame: Baseline (4D-flow MRI performed within 3 days before or after invasive measurements)

Secondary outcomes

  1. : Correlation between 4D Flow MRI measured flows and the percentage of shunt with the incidence of events related to portal hypertension

    Evaluation of the correlation between 4D Flow MRI-measured flows and the percentage of shunt (ratio of splenomesenteric inflow to hepatic venous outflow). Incidence of events related to portal hypertension, including: * Ascites requiring diagnostic or therapeutic paracentesis. * Hospitalization for encephalopathy. * Variceal rupture. * Liver-related death in patients without prior decompensation. Method of Measurement: 4D Flow MRI to assess the flow rates and calculate the shunt percentage (ratio of splenomesenteric inflow to hepatic venous outflow). Clinical event documentation (hospitalization, paracentesis, etc.) in the 6-month follow-up period.

    Time frame: 6 months

  2. Correlation between proteomic signatures and the occurrence of hepatic encephalopathy

    Evaluation of the correlation between proteomic signatures (measured using mass spectrometry) and the onset of hepatic encephalopathy in patients with compensated cirrhosis. Method of Measurement: Mass spectrometry for proteomic analysis. Unit of Measure: Protein concentration (mg/mL).

    Time frame: Occurrence of hepatic encephalopathy will be monitored for 6 months following the TIPS procedure

  3. Correlation between transcriptomic signatures and the occurrence of hepatic encephalopathy

    Evaluation of the correlation between transcriptomic signatures (measured by RNA sequencing) and the onset of hepatic encephalopathy in patients with compensated cirrhosis. Method of Measurement: RNA sequencing for transcriptomic profiling. Unit of Measure: Gene expression levels (RPKM or TPM).

    Time frame: Occurrence of hepatic encephalopathy will be monitored for 6 months following the TIPS procedure

  4. Correlation between metabolomic signatures and the occurrence of hepatic encephalopathy.

    Evaluation of the correlation between metabolomic profiles (measured by mass spectrometry or NMR) and the occurrence of hepatic encephalopathy in patients with compensated cirrhosis. Method of Measurement: Mass spectrometry or NMR for metabolite profiling. Unit of Measure: Metabolite concentration (µM, nmol/mL).

    Time frame: Occurrence of hepatic encephalopathy will be monitored for 6 months following the TIPS procedure

  5. Correlation between viromic signatures and the occurrence of hepatic encephalopathy

    Evaluation of the correlation between viromic signatures (measured by high-throughput sequencing) and the onset of hepatic encephalopathy in patients with compensated cirrhosis. Method of Measurement: High-throughput sequencing for viromic profiling. Unit of Measure: Viral load (copy number of viral genomes per mL) and viral diversity (Shannon diversity index).

    Time frame: Occurrence of hepatic encephalopathy will be monitored for 6 months following the TIPS procedure

  6. Correlation between bacteriomic signatures and the occurrence of hepatic encephalopathy

    Evaluation of the correlation between bacteriomic signatures (measured by 16S rRNA sequencing) and the onset of hepatic encephalopathy in patients with compensated cirrhosis. Method of Measurement: 16S rRNA sequencing for bacterial diversity and abundance analysis. Unit of Measure: Relative bacterial abundance (e.g., % of total microbiome).

    Time frame: Occurrence of hepatic encephalopathy will be monitored for 6 months following the TIPS procedure

  7. Correlation between TIPS diameter and hemodynamic measurements and 4D Flow MRI results before and after TIPS

    Evaluation of the correlation between the TIPS diameter and the hemodynamic measurements (right atrium, inferior vena cava, hepatic veins, portal pressure) and 4D Flow MRI results at three time points. Method of Measurement: TIPS diameter will be measured using imaging techniques such as fluoroscopy or ultrasound. Unit of Measure: TIPS diameter (mm). Pressure (mmHg) at the specified sites.

    Time frame: TIPS diameter measured immediately after the procedure

  8. Correlation between 4D Flow MRI results and hemodynamic measurements before and after TIPS

    Evaluation of the correlation between 4D Flow MRI results and invasive hemodynamic measurements (right atrium, inferior vena cava, hepatic veins, and portal pressure) before, immediately after, and 72 hours after TIPS creation. Method of Measurement: 4D Flow MRI to assess blood flow dynamics. Unit of Measure: Flow rate (mL/min) and velocity (cm/s) for blood flow measurements in the hepatic and portal vasculature. Pressure (mmHg) at the specified sites.

    Time frame: 4D Flow MRI performed within 3 days before and 3 days after TIPS

  9. Correlation between 4D Flow MRI-measured flow rates and the percentage of shunt with the occurrence of TIPS-related and/or portal hypertension-related complications within 6 months following TIPS

    Evaluation of the correlation between 4D Flow MRI-measured flow rates and the percentage of shunt (ratio of splenomesenteric inflow to hepatic venous outflow) before the Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedure with the occurrence of complications related to TIPS and/or portal hypertension within 6 months after TIPS. Complications include: Ascites requiring diagnostic or therapeutic paracentesis,Hospitalization for encephalopathy,Rupture of varices and Liver-related death in patients without a prior history of decompensation. Method of Measurement: The occurrence of complications will be recorded through clinical follow-up, including hospital records and patient reports. Unit of Measure: Complications: Presence/absence of each complication within the 6-month period (binary measure: yes/no). Flow rate: mL/min and velocity (cm/s) for blood flow measurements. Shunt percentage: Percentage (%) of splenomesenteric inflow to hepatic venous outflow.

    Time frame: Complications will be monitored for 6 months following the TIPS procedure

  10. Correlation between 4D Flow MRI flow-rate changes and shunt percentage before and after TIPS, and the occurrence of TIPS- or portal hypertension-related complications within 6 months, in relation to these flow-rate and shunt changes

    Evaluation of TIPS- and/or portal hypertension-related complications within 6 months after TIPS, in relation to changes in 4D Flow MRI-measured flow rates and shunt percentage (pre- and post-TIPS). Complications include: Ascites requiring paracentesis ,Hospitalization for encephalopathy, Rupture of varices, Liver-related death in patients without prior decompensation. Method of Measurement: The occurrence of complications will be recorded through clinical follow-up, including hospital records and patient reports. 4D Flow MRI will assess blood flow rates in the hepatic and splenomesenteric circulation and shunt percentage as the ratio of splenomesenteric inflow to hepatic venous outflow. Unit of Measure: Complications: Presence/absence of each complication within the 6-month period (binary measure: yes/no). Flow rate: mL/min and velocity (cm/s) for blood flow measurements in the hepatic and splenomesenteric vasculature and Shunt percentage (%)

    Time frame: Complications will be monitored for 6 months following the TIPS procedure.

  11. Evaluation of the variation in 4D Flow MRI-measured flow rates and percentage of shunt before and after TIPS, according to TIPS diameter

    Evaluation of the variations in 4D Flow MRI-measured blood flow rates and the percentage of shunt (calculated as the ratio of splenomesenteric inflow to hepatic venous outflow) before and after Transjugular Intrahepatic Portosystemic Shunt (TIPS), in relation to the diameter of the shunt. Method of Measurement: 4D Flow MRI will be used to measure blood flow dynamics in the hepatic and splenomesenteric circulation before and after TIPS. Shunt percentage will be calculated as the ratio of splenomesenteric inflow to hepatic venous outflow, before and after TIPS. TIPS diameter will be measured using imaging techniques such as fluoroscopy or ultrasound. Unit of Measure: Flow rate: mL/min and velocity (cm/s) for blood flow measurements in the hepatic and splenomesenteric vasculature. Shunt percentage: Percentage (%) of splenomesenteric inflow to hepatic venous outflow. TIPS diameter: Millimeters (mm).

    Time frame: Flow measurements and shunt percentage will be assessed before and after TIPS (within 3 days before and 3 days after TIPS).

  12. Correlation between changes in ammonia levels before and after TIPS with changes in percentage of shunt before and after TIPS

    Evaluation of the changes in ammonia levels before and after Transjugular Intrahepatic Portosystemic Shunt (TIPS) in correlation with the changes in the percentage of shunt (calculated as the ratio of splenomesenteric inflow to hepatic venous outflow) before and after TIPS, as measured by 4D Flow MRI. Method of Measurement: Blood samples will be taken to measure serum ammonia levels using standard laboratory techniques (e.g., enzymatic assay or ion-selective electrode). 4D Flow MRI will be used to measure blood flow dynamics and calculate the percentage of shunt as the ratio of splenomesenteric inflow to hepatic venous outflow before and after TIPS. Unit of Measure: Serum ammonia concentration (µmol/L). Percentage (%) of splenomesenteric inflow to hepatic venous outflow

    Time frame: Ammonia levels and shunt percentage will be measured within 3 days before and 3 days after TIPS

  13. Correlation between proteomic signatures (before TIPS and the occurrence of hepatic encephalopathy within 6 months following TIPS

    Evaluation of the correlation between proteomic signatures (measured using mass spectrometry) measured before TIPS and the subsequent development of hepatic encephalopathy within 6 months following TIPS. Method of Measurement: Mass spectrometry for proteomic analysis. Unit of Measure: Protein concentration (mg/mL).

    Time frame: before TIPS, with follow-up for the occurrence of hepatic encephalopathy during the 6 months after TIPS

  14. Correlation between transcriptomic signatures (before TIPS and the occurrence of hepatic encephalopathy within 6 months following TIPS

    Evaluation of the correlation between transcriptomic signatures (measured by RNA sequencing) measured before TIPS and the subsequent development of hepatic encephalopathy within 6 months following TIPS. Method of Measurement: RNA expression levels will be quantified using RNA sequencing or microarrays Unit of Measure: Gene expression levels (RPKM or TPM).

    Time frame: before TIPS, with follow-up for the occurrence of hepatic encephalopathy during the 6 months after TIPS

  15. Correlation between metabolomic signatures (before TIPS and the occurrence of hepatic encephalopathy within 6 months following TIPS

    Evaluation of the correlation between metabolomic profiles (measured by mass spectrometry or NMR) measured before TIPS and the subsequent development of hepatic encephalopathy within 6 months following TIPS. Method of Measurement : mass spectrometry or nuclear magneticresonance (NMR) spectroscopy Unit of Measure : Concentrations of metabolites (µM or nmol/mL)

    Time frame: before TIPS, with follow-up for the occurrence of hepatic encephalopathy during the 6 months after TIPS

  16. Correlation between bacteriomic signatures (before TIPS and the occurrence of hepatic encephalopathy within 6 months following TIPS

    Evaluation of the correlation between bacteriomic signatures (measured by 16S rRNA sequencing) measured before TIPS and the subsequent development of hepatic encephalopathy within 6 months following TIPS. Method of Measurement : 16S rRNA sequencing for bacterial diversity and abundance analysis. Unit of Measure : Relative bacterial abundance (e.g., % of total microbiome).

    Time frame: before TIPS, with follow-up for the occurrence of hepatic encephalopathy during the 6 months after TIPS

  17. Correlation between viromic signatures (before TIPS and the occurrence of hepatic encephalopathy within 6 months following TIPS

    Evaluation of the correlation between viromic signatures (measured by high-throughput sequencing) measured before TIPS and the subsequent development of hepatic encephalopathy within 6 months following TIPS. Method of Measurement: High-throughput sequencing for viromic profiling. Unit of Measure: Viral load (copy number of viral genomes per mL) and viral diversity (Shannon diversity index).

    Time frame: before TIPS, with follow-up for the occurrence of hepatic encephalopathy during the 6 months after TIPS

08

Study locations

2 of 2 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication.Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 15 months after the start.

Of 57 non-industry interventional studies with no phase under Hypertension, Portal, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 72. This study's planned 15 months is below that.

Counting every sponsor, half of 61 studies reached it within 41 months; a quarter within 19 and three quarters within 72.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jun 2026 → Aug 2026 and primary completion Nov 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Apr 28, 2026
StartActual
Aug 25, 2026was Jun 2026
Primary completionEst.
Dec 1, 2027was Nov 2027
CompletionEst.
May 1, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
1 site added. Hôpital Pitié Salpêtrière is now Recruiting
Show site
  • Service d'hépato-gastroentérologie · Paris, France
Oct 13, 2026
Start date
Jun 1, 2026→Aug 25, 2026 (actual)
Oct 13, 2026
Primary completion
Nov 1, 2027→Dec 1, 2027
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    1 site added. Hôpital Pitié Salpêtrière is now Recruiting
    Show site
    • Service d'hépato-gastroentérologie · Paris, France
    Start date Jun 1, 2026→Aug 25, 2026 (now actual)
    Primary completion Nov 1, 2027→Dec 1, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07554183
Collaborators
Sorbonne University, Institute of Cardiometabolism and Nutrition, France
Responsible party
Sponsor
First posted
Apr 28, 2026
Start date
Aug 25, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Louis MEYBLUM, MD
Contact
louis.meyblum@aphp.fr
+331 84 82 82 68
Charles ROUX, MD
Contact
charles.roux@aphp.fr
+33 1 42 16 27 70
Louis MEYBLUM, MD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion